DE1910715A1 - Antimikrobielle Faktoren und deren Verwendung - Google Patents
Antimikrobielle Faktoren und deren VerwendungInfo
- Publication number
- DE1910715A1 DE1910715A1 DE19691910715 DE1910715A DE1910715A1 DE 1910715 A1 DE1910715 A1 DE 1910715A1 DE 19691910715 DE19691910715 DE 19691910715 DE 1910715 A DE1910715 A DE 1910715A DE 1910715 A1 DE1910715 A1 DE 1910715A1
- Authority
- DE
- Germany
- Prior art keywords
- factor
- gel filtration
- water
- charcoal
- antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004599 antimicrobial Substances 0.000 title claims description 14
- 239000000284 extract Substances 0.000 claims description 35
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000002523 gelfiltration Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 210000004556 brain Anatomy 0.000 claims description 17
- 239000002250 absorbent Substances 0.000 claims description 16
- 230000002745 absorbent Effects 0.000 claims description 16
- 210000000952 spleen Anatomy 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 239000003610 charcoal Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 238000005194 fractionation Methods 0.000 claims description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 3
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 210000005171 mammalian brain Anatomy 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 239000000463 material Substances 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 241000304886 Bacilli Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 230000001459 mortal effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010034018 Parosmia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70986968A | 1968-03-04 | 1968-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1910715A1 true DE1910715A1 (de) | 1969-10-09 |
Family
ID=24851616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691910715 Pending DE1910715A1 (de) | 1968-03-04 | 1969-03-03 | Antimikrobielle Faktoren und deren Verwendung |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5512412B1 (enrdf_load_stackoverflow) |
| DE (1) | DE1910715A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2003203A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1262147A (enrdf_load_stackoverflow) |
| NL (1) | NL6903238A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981002520A1 (en) * | 1980-03-05 | 1981-09-17 | G Kaellenius | Compositions for therapeutic or diagnostic use in connection with bacterial infections,and their use |
| WO1981003175A1 (en) * | 1980-05-09 | 1981-11-12 | H Leffler | Carbohydrate derivatives for inhibiting bacterial adherence |
| EP0038511A3 (en) * | 1980-04-17 | 1982-08-18 | Rolf Dr. Schaefer | Wound healing compositions |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK17885D0 (da) * | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | Antiviralt middel |
| US6001998A (en) * | 1994-11-10 | 1999-12-14 | Pfizer Inc | Macrocyclic lactone compounds and their production process |
-
1969
- 1969-03-03 NL NL6903238A patent/NL6903238A/xx unknown
- 1969-03-03 DE DE19691910715 patent/DE1910715A1/de active Pending
- 1969-03-04 FR FR6905873A patent/FR2003203A1/fr not_active Withdrawn
- 1969-03-04 GB GB01397/69A patent/GB1262147A/en not_active Expired
- 1969-03-04 JP JP1609269A patent/JPS5512412B1/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981002520A1 (en) * | 1980-03-05 | 1981-09-17 | G Kaellenius | Compositions for therapeutic or diagnostic use in connection with bacterial infections,and their use |
| EP0038511A3 (en) * | 1980-04-17 | 1982-08-18 | Rolf Dr. Schaefer | Wound healing compositions |
| WO1981003175A1 (en) * | 1980-05-09 | 1981-11-12 | H Leffler | Carbohydrate derivatives for inhibiting bacterial adherence |
| US4464360A (en) * | 1980-05-09 | 1984-08-07 | Hakon Leffler | Glycosphingalipids for inhibiting bacterial adherence |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1262147A (en) | 1972-02-02 |
| JPS5512412B1 (enrdf_load_stackoverflow) | 1980-04-02 |
| NL6903238A (enrdf_load_stackoverflow) | 1969-09-08 |
| FR2003203A1 (fr) | 1969-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2725204C2 (de) | Verfahren zum Herstellen eines die unspezifische Immunität stimulierenden löslichen Mikroorganismenextrakts und diesem enthaltendes Arzneimittel | |
| DE3209419A1 (de) | Hautregenerierendes, kosmetisches praeparat und verfahren zu dessen herstellung | |
| DE2441454A1 (de) | Verfahren zur herstellung eines heilmittels fuer leukaemie | |
| DE69936153T2 (de) | Biologischaktive Labdan- oder Labdenderivate aus Cistus. | |
| DE69722514T2 (de) | Aus dictyotales extrahierte substanzen, ihr herstellungsverfahren und sie enthaltende zusammensetzungen | |
| DE60129322T2 (de) | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen | |
| DE2923144C2 (de) | Impfstoff zur Prophylaxe und Behandlung von durch Trichophyton mentagrophytes hervorgerufenen Trichophytien bei Pelztieren und Kaninchen und seine Herstellung | |
| DE69026371T2 (de) | Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren | |
| DE2645993A1 (de) | Mittel gegen myeloische leukaemie und sein herstellungsverfahren | |
| EP0220453B1 (de) | Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung | |
| EP0493662B1 (de) | Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge | |
| DE1910715A1 (de) | Antimikrobielle Faktoren und deren Verwendung | |
| EP0310757B1 (de) | Verfahren zur Herstellung eines Propolis-Äthanolextraktes | |
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE2262427C3 (de) | Immunostimulierendes Mittel | |
| DE102016116126A1 (de) | Antibakterielle Zusammensetzung, umfassend einen Pflanzenextrakt, Verfahren zur Gewinnung des Extrakts, pharmazeutische Zusammensetzung und deren Verwendung | |
| AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
| CH640244A5 (en) | Biologically active substance | |
| DE10085492B4 (de) | Antimonocytenaktivität von extrakten von Betelpfefferblättern | |
| DE1037651B (de) | Verfahren zur Herstellung eines therapeutisch wirksamen Extraktes aus dem Kittharz der Apis mellifica | |
| DE3116695A1 (de) | "neues pflanzenextrakt und ein dieses enthaltendes arzneimittel und dessen anwendung sowie verfahren zur herstellung des extrakts" | |
| DE1115888B (de) | Verfahren zur Herstellung eines Streptokinase-Praeparates | |
| EP2606902A1 (de) | Extrakt aus Rhus copallina als Arzneimittel | |
| DE338166C (de) | Verfahren zur Herstellung unschaedlicher Impfstoffe aus gifthaltigen pathogenen Mikroorganismen | |
| AT200257B (enrdf_load_stackoverflow) |